Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells

European Journal of Gynaecological Oncology

Volumn 31, Issue 4, 2010, Pages 402-410

  Chao, K C ^a   Chang, C C ^a   Yen, M S ^a   Wang, P H ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Histone deacetylase inhibitors; Multidrug resistance associated proteins; Multidrug resistant protein; Ovarian cancer cell line

Indexed keywords

BUTYRIC ACID; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; TRICHOSTATIN A; VORINOSTAT; ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BUTYRIC ACID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; CELL VIABILITY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; RNA PURIFICATION; TREATMENT RESPONSE; FEMALE; GENETICS; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BUTYRATES; CELL LINE, TUMOR; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; OVARIAN NEOPLASMS;

EID: 77956110205     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Chao K.C., Chang C.C., Yen M.S., Wang P.H., Ng.H.T.: "Granulocyte colony-stimulating factor on the growth of human ovarian carcinoma cells in vitro". Gynecol. Obstet. Invest., 1999, 48, 280.
2. Chao K.C., Wang P.H., Yen M.S., Chang C.C., Chi C.W.: "The role of estrogen and progesterone in the survival of ovarian tumors-a study of the human ovarian adenocarcinoma cell line OC-117-VGH". J. Chin. Med. Assoc., 2005, 68, 360.
3. Harrison D.J.: "Molecular mechanisms of drug resistance in tumours". J. Pathol., 1995, 175, 7.
4. Wang P.H., Chang C.: "Androgens and ovarian cancer". Eur. J. Gynecol. Oncol., 2004, 25, 157.
5. Duan Z., Brakora K.A., Seiden M.V.: "Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells". Mol Cancer Ther., 2004, 3, 833.
6. Ohishi Y., Oda Y., Uchiumi T., Kobayashi H., Hirakawa T., Miyamoto S. et al.: "ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma". Clin. Cancer Res., 2002, 8, 3767.
7. Kahnberg P., Lucke A.J., Glenn M.P., Boyle G.M., Tyndall J.D., Parsons P.G., Fairlie D.P.: "Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid". J. Med. Chem., 2006, 49, 7611.
8. Xu W.S., Parmigiani R.B., Marks P.A.: "Histone deacetylase inhibitors: molecular mechanisms of action". Oncogene, 2007, 26, 5541.
9. Bolden J.E., Peart M.J., Johnstone R.W.: "Anticancer activities of histone deacetylase inhibitors". Nat. Rev. Drug Discov., 2006, 5, 769.
10. Yoo C.B., Jones P.A.: "Epigenetic therapy of cancer: past, present and future". Nat. Rev. Drug Discov., 2006, 5, 37.
11. Minucci S., Pelicci P.G.: "Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer". Nat. Rev. Cancer 2006, 6, 8.
12. Candelaria M., Gallardo-Rincón D., Arce C., Cetina L., Aguilar-Ponce J.L., Arrieta O. et al.: "A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors". Ann. Oncol., 2007, 18, 1529.
13. Lin C.T., Lai H.C., Lee H.Y., Lin W.H., Chang C.C., Chu T.Y. et al.: "Valproic acid resensitizes cisplatin-resistant ovarian cancer cells". Cancer Sci., 2008, 99, 1218.
14. Wang P.H., Li Y.F., Juang C.M., Lee Y.R., Chao H.T., Tsai Y.C., Yuan C.C.: "Altered mRNA expression of sialyltransferase in squamous cell carcinomas of the cervix". Gynecol. Oncol. 2001, 83, 121.
15. Wang P.H., Lee W.L., Lee Y.R., Juang C.M., Chao H.T., Tsai Y.C., Yuan C.C.: "Enhanced expression of -2,6-sialyltransferase ST6Gal I in cervix squamous cell carcinoma". Gynecol. Oncol., 2003, 89, 395.
16. Hsu C.C., Lin T.W., Chang W.W., Wu C.Y., Lo W.H., Wang P.H., Tsai Y.C.: "Soyasaponin-I-modified invasive behavior of cancer by changing cell surface sialic acids". Gynecol. Oncol., 2005, 96, 415.
17. Noonan K.E., Beck C., Holzmayer T.A., Chin J.E., Wunder J.S., Andrulis I.L.: "Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction". Proc. Natl. Acad. Sci. USA, 1990, 87, 7160.
18. Payen L., Courtois A., Campion J.P., Guillouzo A., Fardel O.: "Characterization and inhibition by a wide range of xenobiotics of organic anion excretion by primary human hepatocytes". Biochem. Pharmacol., 2000, 60, 1967.
19. Weichert W., Denkert C., Noske A., Darb-Esfahani S., Dietel M., Kalloger S.E. et al.: "Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas". Neoplasia, 2008, 10, 1021.
20. Yap O.W., Bhat G., Liu L., Tollefsbol T.O.: "Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells". Anticancer Res., 2009, 29, 139.
21. Bazzaro M., Lin Z., Santillan A., Lee M.K., Wang M.C., Chan K.C. et al.: "Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor". Clin. Cancer Res., 2008, 14, 7340.
22. Blagosklonny M.V., Giannakakou P., Wojtowicz M., Romanova L.Y., Ain K.B., Bates S.E., Fojo T.: "Effects of P53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells". J. Clin. Endocrinol. Metab., 1998, 83, 2516.
23. Tabe Y., Konopleva M., Contractor R., Munsell M., Schober W.D., Jin L. et al.: "Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells". Blood, 2006, 107, 1546.
24. Castro-Galache M.D., Ferragut J.A., Barbera V.M., Martin-Orozco E.M., Gonzales-Ros J.M., Garcia-Morales P., Saceda M.: "Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors". Int. J. Cancer, 2003, 104, 579.
25. Mickley L.A., Bates S.E., Riehen N.D., Currier S., Tanaka S., Foss F. et al.: "Modulation of the expression of a multidrug resistance gene (mdr-1/ Pglycoprotein) by differentiating agents". J. Biol. Chem., 1989, 264, 18031.
26. Satake S., Sugawara I., Watanabe M., Takami H.: "Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines". Cancer Lett., 1997, 116, 33.
27. Lautier D., Canitrot Y., Deeley R.G., Cole S.P.: "Multidrug resistance mediated by the multidrug resistance protein (MRP) gene". Biochem. Pharmacol., 1996, 52, 967.
28. Sonnemann J., Hüls I., Sigler M., Palani C.D., Hong le T.T., Völker U. et al.: "Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells". Oncol. Rep., 2008, 20, 219.